Study of ACT-293987 (NS-304) in Pulmonary Arterial Hypertension (PAH)

Update Il y a 4 ans
Reference: NCT00993408

Woman and Man

Extract

This is a multi-centre, multinational, open-label, single-dose acute hemodynamic study followed by randomized, double-blind, parallel-group, placebo controlled study. Eligible subjects will undergo an open-label, single-dose acute hemodynamic study with ACT-293987(NS-304) and 21 weeks of double-blind treatment during which subjects will receive either ACT-293987 (NS-304) or placebo b.i.d. Subjects who have completed the double-blind study can enter the open extension study (separate protocol) and receive administration of ACT-293987 (NS-304) if the subject wishes and the Investigator considers it appropriate.


Inclusion criteria

  • pulmonary arterial hypertension


Links